Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of GSK3923868 in Healthy and Asthmatic Participants
NCT04585009Phase 1Completed
- Sponsor
- GSK
- Start
- Oct 2020
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GSK3923868 in asthma and chronic obstructive pulmonary disease (COPD) (5 cohorts), sponsored by GSK. Primary endpoints: Number of Participants With Adverse Events and Serious Adverse Events, Number of Participants With Clinically Significant Changes in Clinical Chemistry and Hematology Laboratory Parameters at Day 8 and 2 more. Started Oct 2020; status: completed.
02
Drugs
GSK3923868
03
Conditions
asthmachronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT04585009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04585009.